'This year there is a sharp spike in fever cases, and it seems to be more than the pre-COVID-19 levels.'
The efficacy of the vaccine, developed by the Gamalaya Centre, was demonstrated on the basis of a first interim analysis obtained 21 days after the first injection.
The number of cases due to the mosquito-transmitted disease in the southern state went went up to 14 on Friday following confirmation of 13 additional samples by the National Institute of Virology.
The VL-SRSAM, which DRDO developed for the Indian Navy, was fired from a warship at a high-speed aerial target mimicking incoming enemy aircraft.
Since the trial participants were not exposed to the coronavirus after vaccination, the scientists said it is not possible for the current study to determine the efficacy of the candidate vaccine.
With a revival in demand and consumption, FMCG companies are looking forward to 2022 with positivity and hopes of sustaining a healthy growth trend across both rural and urban markets while gearing up to cater to the ever-increasing digitally active consumers and tackle the challenge of higher commodity prices. Health and wellness and convenience are going to remain key trends and FMCG companies are strengthening their core brands, driving premiumisation across their portfolios with targeted innovations as consumers are gravitating towards trusted brands looking for quality, purity and hygiene, in continuation of the trend that started since the pandemic last year. FMCG makers are accelerating digitalisation and are investing in building capability in e-commerce and Direct-to-Consumer channels, identifying it as a key vector of their growth as the threat of a possible third wave is still not away.
'Football is in full solidarity with all the people affected in Ukraine. Both Presidents hope that the situation in Ukraine will improve significantly and rapidly so that football can again be a vector for unity and peace.'
'On the LAC, China can undertake military action at any place with much fewer resources. It can do 'salami slicing'.'
The study also noted that the booster dosage of the company's COVID-19 vaccine Vaxzevria also increased the immune response to Beta, Delta, Alpha and Gamma SARS-CoV-2 variants.
The first nasal vaccine against COVID-19, developed by Bharat Biotech, has received regulator's nod for conducting phase 2 clinical trials, the Department of Biotechnology said on Friday.
While the vaccine could be available at $3-6 (Rs 225 to Rs 550) per dose, herd immunity might be two years away due to implementation challenges, it said, adding the experience in large scale adult vaccination programmes is thin.
Chikungunya death toll climbs to 12 while the toll due to dengue rises to 18.
The researchers, working in an 'unprecedented' vaccine development effort to prevent COVID-19, said they have started screening healthy volunteers (aged 18-55) from Friday for their upcoming trial in the Thames Valley Region of England.
The Drugs Controller General of India (DCGI) has granted permission to the Serum Institute of India (SII) to manufacture the Sputnik COVID-19 vaccine in India for examination, test and analysis with certain conditions, official sources said.
The government is hopeful of a speedy launch of single-dose COVID-19 vaccine Sputnik Light in India and all stakeholders, including the Russian manufacturer and its Indian partners, have been directed to fast-track the application and regulatory approval procedures for the jab to boost the country's vaccination drive, sources said.
Most traditional health insurance plans didn't cover the cost of such treatments earlier, but several recently launched policies do offer such coverage -- some as a rider, and a few as standalone covers, points out Sarbajeet K Sen.
Bharat Biotech is targeting to manufacture one billion doses of its intra-nasal vaccine in 2022 which is under clinical trials now.
'Your body will be able to deal with Omicron at any time, but it depends (on when) if you are vaccinated.'
A pet's first line of defence is a well-prepared owner.
The first COVID-19 vaccine to reach phase I clinical trial is safe, well-tolerated, and capable of generating an immune response against the novel coronavirus in humans, says a new research published in The Lancet journal.
The vector-borne disease has also affected over 1,150 people this season.
The aircraft was forced to land at Jaipur airfield by air defence aircraft of the IAF, they said.
The survey covered 1,210 IT executives and technology professionals from North America, the United Kingdom, Australia, New Zealand, Singapore and India. In India, 202 respondents from businesses with more than 500 employees across 18 industry verticals completed the survey. Overall, 89 per cent of the respondents said implementing a work-from-home policy had increased security challenges for their organisations. The risk posed by shadow IT was especially high, with 89 per cent of companies having no control over the software that employees purchase and install on their devices.
'A good 30 per cent of people will still get infected after getting the Covishield vaccine.'
Remember, the security of your job primarily depends on two major factors -- how relevant you are for the organisation and how the organisation is aligned to its stakeholders (investors, clients and employees)
If the vaccine is recommended for use as a booster against Omicron, it may significantly boost the demand for Covishield in India.
The Russian vaccine has been registered in more than 55 countries and is gaining recognition in the virtual world -- being the only to have its own Facebook page, YouTube channel and a Twitter handle, reports Aneesh Phadnis
Nobel laureate Peter Doherty says his 'big worry' is there could be refusals for other vaccines if doubts over its safety turn out to be true.
Chikungunya and dengue have claimed at least 31 lives and affected nearly 3,000 people in Delhi.
Delhi CM Arvind Kejriwal shrugged off responsibility saying that he and his ministers had no powers and one should ask the PM.
The research, published in the journal Scientific Reports, provided the first experimental evidence on the capacity of SARS-CoV-2, the virus that causes COVID-19 disease, to infect and be transmitted by mosquitoes.
The government may look at areas around Thonnakkal, in Thiruvananthapuram district, for the facility. If successful, this would be one of the few sites of Sputnik V owned by Russian firms outside that country. Shine Jacob and Sohini Das report.
Security incidents became more costly and harder to contain due to drastic operational shifts during the pandemic with the cost of data breaches to Indian organisations rising close to 18 per cent to Rs 16.5 crore on an average between May 2020 and March 2021, according to a report by IBM. The study pointed towards similar trends in other parts of the world with data breaches costing surveyed companies $4.24 million per incident on an average - the highest in the report's 17-year history.
At least 1,158 cases of dengue have been reported in the national capital with nearly 390 of them being recorded in the first 10 days of September, the month in which the vector-borne disease begins to peak.
We are entering 2022, facing another infectious variant, with much the same baseless confidence, notes Mihir S Sharma.
Dr Samar Sen Popuri from Hyderabad tells Rediff.com's A Ganesh Nadar what he would like to see in Finance Minister Nirmala Sitharaman's Budget.
India is not keen to 'bow down' to demands related to indemnity against legal liabilities in case any vaccine recipient develops severe adverse reactions post inoculation.
As per RDIF, Sputnik V has a number of key advantages, including that there are no strong allergies caused by Sputnik V.
'We expect to get the approval in the next few weeks,' says Deepak Sapra, CEO, API and pharmaceutical services, Dr Reddy's Laboratories (DRL).
